06.02.2024 - Company opens own physician-led laboratory, ‘European Oncology Lab’ (EOL), thereby offering ColoAlert as a laboratory medical service directly to physicians and patientsBERKELEY, Calif. and MAINZ, Germany, Feb. 06, 2024 (GLOBE NEWSWIRE) - Mainz . Seite 1
29.11.2023 - BERKELEY, Calif. and MAINZ, Germany, Nov. 29, 2023 (GLOBE NEWSWIRE) - Mainz Biomed N.V. (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a molecular genetics diagnostic company specializing in the early detection of cancer, announces that its .
04.10.2023 - Strategic Collaboration Elevates Early Cancer Detection, Bringing State-of-the-Art Diagnostic Capabilities to Romanian PopulationBERKELEY, Calif. and MAINZ, Germany, Oct. 04, 2023 (GLOBE NEWSWIRE) - Mainz Biomed NV (NASDAQ:MYNZ) (“Mainz Biomed” or . Seite 1
22.08.2023 - Strategic Partnership Aims to Revolutionize Cancer Screening and Enhance Healthcare Outcomes, Bringing Innovative Genetic Testing Solutions to Individuals Across PolandBERKELEY, Calif. and MAINZ, Germany, Aug. 22, 2023 (GLOBE NEWSWIRE) - Mainz . Seite 1